Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by CenterBook Partners LP

by · The Markets Daily

CenterBook Partners LP increased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) by 237.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,594,229 shares of the company’s stock after purchasing an additional 1,122,154 shares during the quarter. CenterBook Partners LP owned approximately 0.99% of Xeris Biopharma worth $7,445,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in XERS. FORA Capital LLC purchased a new stake in shares of Xeris Biopharma during the 1st quarter worth approximately $60,000. R Squared Ltd raised its stake in Xeris Biopharma by 27.7% during the 1st quarter. R Squared Ltd now owns 15,730 shares of the company’s stock worth $86,000 after acquiring an additional 3,410 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Xeris Biopharma in the first quarter valued at $86,000. Aigen Investment Management LP acquired a new position in Xeris Biopharma in the first quarter valued at $92,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Xeris Biopharma during the second quarter worth about $95,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on XERS. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, October 8th. Piper Sandler boosted their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Zacks Research downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $18.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.58.

Get Our Latest Stock Report on XERS

Insider Activity

In other news, insider John Patrick Shannon, Jr. sold 23,242 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $7.46, for a total transaction of $173,385.32. Following the transaction, the insider directly owned 2,643,153 shares in the company, valued at $19,717,921.38. The trade was a 0.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Marla Persky sold 15,500 shares of the firm’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $7.72, for a total transaction of $119,660.00. Following the completion of the sale, the director owned 142,000 shares of the company’s stock, valued at approximately $1,096,240. The trade was a 9.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 97,641 shares of company stock valued at $750,859. 6.47% of the stock is owned by corporate insiders.

Xeris Biopharma Trading Down 0.1%

NASDAQ:XERS opened at $6.83 on Friday. Xeris Biopharma Holdings, Inc. has a 12-month low of $3.02 and a 12-month high of $10.08. The stock’s 50 day simple moving average is $8.28 and its 200-day simple moving average is $6.57. The firm has a market cap of $1.13 billion, a P/E ratio of -68.29 and a beta of 0.21.

Xeris Biopharma Profile

(Free Report)

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

See Also

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report).